FAM
ENTA icon

Fred Alger Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Fred Alger Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,000
Closed -$253K – 502
2019
Q2 		$253K Buy
+3,000
New +$270K ﹤0.01% 398
2018
Q2 		– Sell
-4,000
Closed -$324K – 555
2018
Q1 		$324K Buy
+4,000
New +$308K ﹤0.01% 388

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Fred Alger Management's ENTA Position: Q3 2019 in Review

Fred Alger Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2019, closing a stake of 3,000 shares — an estimated $253K sold.

Fred Alger Management first reported a position in ENTA in Q1 2018 and held it in 2 quarters. The position peaked at $324K in Q1 2018. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

  • Fred Alger Management reported no remaining Enanta Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Fred Alger Management sold 3,000 Enanta Pharmaceuticals shares in Q3 2019, an estimated $253K.
  • Fred Alger Management first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Fred Alger Management's Enanta Pharmaceuticals position peaked at $324K in Q1 2018.
  • 176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Fred Alger Management's 13F filing for Q3 2019, filed 14 Nov 2019.